Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04668300 · ClinicalTrials.gov registry record · Phase 2
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma
A Phase 2 study of Recurrent Osteosarcoma and Metastatic Osteosarcoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT04668300 is a Phase 2 study of Recurrent Osteosarcoma and Metastatic Osteosarcoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 75 participants, above the 61-participant average among 13 other Recurrent Osteosarcoma trials with a reported enrollment target (23% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04668300, a Phase 2 study of Recurrent Osteosarcoma and Metastatic Osteosarcoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial investigates how well oleclumab and durvalumab work in treating patients with sarcoma that has come back (recurrent) or does not respond to treatment (refractory) or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as oleclumab and durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Conditions Studied
Interventions
- BIOLOGICAL Durvalumab
- BIOLOGICAL Oleclumab
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2020-11-26 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04668300
The ClinicalTrials.gov registry entry for NCT04668300 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 61-participant average among 13 other Recurrent Osteosarcoma trials with a reported enrollment target (23% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Recurrent Osteosarcoma appearing as the primary indexed condition, and to 2 interventions - of which Durvalumab is the first listed.
NCT04668300 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04668300 about?
NCT04668300 is a clinical study titled "Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma". This phase II trial investigates how well oleclumab and durvalumab work in treating patients with sarcoma that has come back (recurrent) or does not respond to treatment (refractory) or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as oleclumab a...
What is the current status of trial NCT04668300?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2020-11-26. Estimated completion is 2026-06-30.
What conditions does trial NCT04668300 study?
This clinical trial studies the following conditions: Recurrent Osteosarcoma, Metastatic Osteosarcoma, Refractory Osteosarcoma, Metastatic Dedifferentiated Liposarcoma, Recurrent Dedifferentiated Liposarcoma.
What interventions are being tested in trial NCT04668300?
The interventions under investigation include: Durvalumab (BIOLOGICAL), Oleclumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04668300?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04668300 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Osteosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
RECRUITING · Phase 2
-
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
ACTIVE NOT RECRUITING · Phase 2
-
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
COMPLETED · Phase 2
-
Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.